Bakonyi A, Kovács L, Duong H T, Arányi P
Institute for Drug Research, Budapest, Hungary.
Acta Physiol Hung. 1994;82(1):29-36.
The tripeptide aldehyde GYKI-14766 (D-MePhe-Pro-Arg-H) synthesized by Bajusz et al. in 1975 is a specific, reversible thrombin inhibitor. It was found effective in vitro in clotting time assays as well as in vivo in thrombosis models. To study the biochemical effects of the inhibitor various experimental setups were applied. First we measured the binding of thrombin to platelets using 125J-thrombin. KD was 55 nM. Second, 125J-thrombin was displaced by thrombin or by a GYKI-14766-thrombin-complex with similar efficacy. However, the binding of thrombin to the platelets increased the intracellular free Ca2+ concentration, but the inhibitor-thrombin complex did not influence it. Analyzing the kinetics of the reactions involved we found that the formation of the GYKI-14766-thrombin complex was slower than the triggering of the platelet Ca2+ signal by thrombin.
1975年由巴尤斯等人合成的三肽醛GYKI - 14766(D - 甲基苯丙氨酸 - 脯氨酸 - 精氨酸 - H)是一种特异性、可逆的凝血酶抑制剂。它在体外凝血时间测定以及体内血栓形成模型中均被发现有效。为研究该抑制剂的生化作用,采用了各种实验设置。首先,我们使用¹²⁵I - 凝血酶测量凝血酶与血小板的结合。解离常数(KD)为55纳摩尔。其次,凝血酶或与GYKI - 14766 - 凝血酶复合物以相似效力取代¹²⁵I - 凝血酶。然而,凝血酶与血小板的结合增加了细胞内游离钙离子浓度,但抑制剂 - 凝血酶复合物并未对其产生影响。分析所涉及反应的动力学,我们发现GYKI - 14766 - 凝血酶复合物的形成比凝血酶触发血小板钙离子信号的速度慢。